Michael Pfreundschuh
Pfreundschuh, Michael 1949-2018
Pfreundschuh, M. (Michael)
Pfreundschuh, Michael
Pfreundschuh, Michael (1949- ).
Pfreundschuh, M.
VIAF ID: 8943245 (Personal)
Permalink: http://viaf.org/viaf/8943245
Preferred Forms
- 100 0 _ ‡a Michael Pfreundschuh
- 100 1 _ ‡a Pfreundschuh, M.
-
- 100 1 _ ‡a Pfreundschuh, M. ‡q (Michael)
-
- 100 1 0 ‡a Pfreundschuh, M. ‡q (Michael)
-
-
-
- 100 1 _ ‡a Pfreundschuh, Michael ‡d 1949-2018
4xx's: Alternate Name Forms (11)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV | |
Diffus großzelliges B-Zell-Lymphom Informationen für Patienten | |
Einfluss einer Barorezeptorenreizung auf den Reizerfolg einer elektrischen Reizung der "defence area" des Hypothalamus | |
Fisiopatología y bioquímica con 112 tablas | |
Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS | |
Incidence and inheritance of hyperphosphorylated paratarg-7 in patients with Waldenstrom's macroglobulinaemia in Sweden | |
Increased levels of circulating cytokines in patients with untreated Hodgkin's disease | |
Influence of telomere length on short-term recovery after allogeneic stem cell transplantation | |
Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors. | |
[Intermediate results of therapy studies HD1, HD2 and HD3 of the German Hodgkin Study Group] | |
Intra-articular glucocorticosteroid injection into sternocostoclavicular joints in patients with SAPHO syndrome | |
[Ki-ras mutation as a molecular tumor marker for carcinoma of the pancreas] | |
Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation | |
Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma | |
Mantle cell lymphoma: biological insights and treatment advances | |
Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. | |
Mature T-cell and NK/T-cell neoplasms. | |
MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing | |
MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies | |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas | |
Mitofilin and titin as target antigens in melanoma-associated retinopathy | |
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Gr | |
Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease | |
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma | |
N-ras genes are not mutated in Hodgkin and Reed-Sternberg cells: results from single cell polymerase chain-reaction examinations | |
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity | |
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer | |
Neue Aspekte für die Chemotherapie von Malignomen | |
New aspects in the diagnosis and treatment of Hodgkin's disease | |
[New diagnostic and therapeutic strategies for aggressive lymphomas] | |
New perspectives in immunotherapy: adhesion molecules, superantigens, heat-shock proteins and cytokine antagonists | |
Notch- and vitamin D signaling in 1,25(OH)2D3-resistant glioblastoma multiforme (GBM) cell lines | |
A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing | |
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients | |
Onkologische Therapie Leitlinien und Schemata zur Diagnostik, Therapie und Nachsorge | |
Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources | |
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. | |
[Palliative medical therapy of malignant diseases] | |
Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. | |
Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma | |
Pathophysiologie - Pathobiochemie | |
Pharmakokinetik des monoklonalen anti-CD20 Antikörpers Rituximab bei aggressiven CD20 positiven B-Zell-Lymphomen | |
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma | |
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. | |
Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications | |
Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study | |
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. | |
Prognostic significance of maximum tumour | |
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network | |
Progranulin autoantibodies in systemic sclerosis and autoimmune connective tissue disorders: A preliminary study | |
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL) | |
Proinflammatory progranulin antibodies in inflammatory bowel diseases | |
Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer | |
Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma | |
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes | |
R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes | |
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma | |
Rapid reconstitution of CMV-specific T-cells after stem-cell transplantation. | |
Recombinant antigen expression on yeast surface | |
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial | |
Response: Intrathecal methotrexate and central nervous system events | |
Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma | |
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial | |
Rituximab for the treatment of diffuse large B-cell lymphomas | |
Rituximab in high-grade lymphoma | |
Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. | |
Rituximab maintenance therapy in central nervous system lymphoma? | |
Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies. | |
Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. | |
RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells | |
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group | |
Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS/multiple myeloma | |
Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. | |
Serological identification of human tumor antigens | |
Serological immune response to cancer testis antigens in patients with pancreatic cancer | |
Serologische Analyse von Oberflächenantigenen menschlicher Neoplasien | |
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening | |
Therapiefortschritte bei aggressiven Lymphomen |